Claudia Bohnert

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The NK3 receptor is a GPCR that is prominently expressed in limbic areas of the brain, many of which have been implicated in schizophrenia. Phase II clinical trials in schizophrenia with two selective NK3 antagonists (osanetant and talnetant) have demonstrated significant improvement in positive symptoms. The objective of this study was to characterize the(More)
  • 1